Supplement analysis backed by scientific evidence · PT

← All supplements
Moderate evidenceHeart & metabolic

Propionyl-L-Carnitine

Propionyl-L-carnitine is a carnitine ester with better uptake into vascular and cardiac tissue than plain L-carnitine, studied mainly as a drug for peripheral arterial disease. Early trials showed real walking-distance gains, but the 2021 Cochrane review — which added larger, better-controlled studies — found the effect uncertain and clinically small.

What the science says

  • Walking distance in intermittent claudication: early promise, uncertain on Cochrane review Moderate evidence

    A 2013 systematic review and meta-analysis of PLC in claudication found significant improvements in maximal walking distance (roughly 50-60 m over placebo) across trials. The 2021 Cochrane review reassessed the evidence and rated certainty as low, concluding the effect on maximal and pain-free walking distance may be small or absent and that larger, better-designed trials are needed. Supervised exercise therapy remains the far stronger first-line intervention.

  • Better tissue delivery than plain L-carnitine — for vascular tissue specifically Moderate evidence

    The propionyl group improves transport across cell membranes into ischemic muscle and endothelium and supplies propionyl-CoA to the Krebs cycle, which is the rationale for testing PLC rather than L-carnitine in ischemic conditions. This is a genuine pharmacological distinction, unlike most supplement "advanced forms" — but it earns PLC a specific clinical niche, not general superiority for energy or fat loss.

  • Erectile dysfunction and heart failure data are preliminary Limited evidence

    Small trials have combined PLC (typically 2 g/day) with sildenafil in men with diabetes and ED and reported greater improvement than sildenafil alone, but these were preliminary, small, and largely from a single research group. Chronic heart failure and Peyronie's trials are similarly small. None of this reaches the standard needed for a general recommendation.

Dosage & safety

Studied doseClaudication trials used 1-2 g/day orally (usually 600 mg two to three times daily) for 6-12 months; intravenous protocols were used in hospital settings. ED adjunct studies used about 2 g/day. Note that PLC is a licensed medicine in parts of Europe (as a treatment for peripheral arterial disease and carnitine deficiency), so availability as a supplement varies by country.
SafetyGenerally well tolerated; reported effects include nausea, heartburn, diarrhea and a fishy body odor at higher doses. Carnitine supplementation increases gut bacterial production of TMAO, which has been associated with cardiovascular risk in observational work — a theoretical concern for long-term use in people who already have vascular disease, though not demonstrated as harm in the trials. May potentiate warfarin (INR monitoring advised) and may lower seizure threshold in susceptible individuals. Thyroid patients should be aware carnitine can antagonize thyroid hormone action. Prescription status varies by country; discuss with a doctor if you have PAD, heart failure, or take anticoagulants. Not banned in sport.

Scientific references

Where to buy

Life Extension, Optimized Carnitine, 60 Capsules

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Heart & metabolic